Introduction
Neuropsychology plays an important role in evaluating the neuropsychiatric effects of brain tumors and cancers by assessing attention, executive functioning, language, visuospatial, and memory functioning (Dharia et al., 2024; Parsons & Dietrich, 2021). These cognitive evaluations are crucial for establishing both a baseline before treatment, and for monitoring change over time (Chieffo et al., 2023; Hoffnung, 2016). Optimal cognitive rehabilitation and surgical planning is the goal, especially as promising treatments are forthcoming (Parsons & Sabsevitz, 2023). Cognitive profiles can provide prognostic factors, predicting survival outcomes and aiding in personalized treatment approaches (Dharia et al., 2024; Parsons & Dietrich, 2021).
Brain tumor characteristics (i.e., type, size, location) can significantly influence neuropsychiatric functioning. Firstly, high-grade tumors (e.g., gliomas) tend to cause more severe cognitive impairments due to their aggressive growth and infiltration into surrounding tissue, compared to low-grade tumors (Dharia et al., 2024; Parsons & Dietrich, 2021). Secondly, tumor size also correlates with cognitive deficits, with larger tumors leading to greater disruption of cognitive functions and connections (Parsons & Sabsevitz, 2023). The specific tumor location is another important factor. For example, frontal lobe tumors may result in behavioral changes and executive dysfunction, while those in the temporal lobe can affect memory and language (Chieffo et al., 2023; Hoffnung, 2016). Tumors located in regions essential to core cognitive functions are more likely to result in marked deficits, as they disrupt key neural pathways (Parsons & Dietrich, 2021). Individual variability, such as age and premorbid cognitive functioning, not surprisingly, contributes to outcomes (Chieffo et al., 2023).
Patients with brain tumors often experience neurocognitive deficits, including short-term and long-term memory difficulties, particularly when the temporal lobe is affected (Parsons & Dietrich, 2021). Attention dysfunction, including challenges with sustained attention and distractibility, and executive dysfunction affecting planning, organizing, and decision-making, can be present (Chieffo et al., 2023; Hoffnung, 2016). Language difficulties, such as trouble with word retrieval and understanding spoken or written language, are also prevalent (Chieffo et al., 2023). Visuospatial deficits, slower processing speeds, and cognitive fatigue further complicate daily activities, leading to challenges in performing tasks efficiently (Parsons & Dietrich, 2021; Hoffnung, 2016). Neuropsychiatric symptoms are common behavioral and emotional changes associated with cognitive impairments (Chieffo et al., 2023). These deficits, which vary based on the tumor’s location, type, and treatment, necessitate comprehensive assessment and management to improve patients’ quality of life (QoL; Parsons & Sabsevitz, 2023).
The treatment of brain tumors may involve a combination of surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy (Dharia et al., 2024). Surgical resection may cause immediate cognitive deficits, particularly if the tumor is near critical areas responsible for memory, language, or executive functions (Dharia et al., 2024). Over time, some patients experience recovery of skills, while others may face persistent deficits (Parsons & Dietrich, 2021). Fatigue, memory deficits, and slower processing speed can present after radiation therapy, with some cognitive changes being both acute and long-term. These effects can be especially prevalent in patients receiving whole-brain radiation, which can cause radiation-induced cognitive decline that may not manifest until months or years after treatment (Dharia et al., 2024; Parsons & Dietrich, 2021). Chemotherapy contributes to attention and memory deficits during and after treatment, with some patients experiencing lasting cognitive difficulties, especially after multi-agent regimens (Chieffo et al., 2023). When treatments are combined, patients may experience compounded cognitive challenges, as the cumulative neurotoxic effects of surgery, radiation, and chemotherapy can intensify cognitive decline (Parsons & Dietrich, 2021). However, individual variability plays an important role, with factors like age, baseline cognitive function, and tumor characteristics influencing the severity of cognitive changes (Hoffnung, 2016).
Case Study
A 67-year-old, right-handed woman presented with expressive language difficulties within the context of two previous resections (September 2023; February 2024) of a recurrent left temporal glioblastoma. Medical history is significant for hypothyroidism and osteoarthritis. Her psychiatric history is notable for increasingly prevalent symptoms of depression, with onset beginning after the first glioblastoma resection. She began experiencing recurrent thoughts about her future and potential preparations for death, given her health status. Minimal changes were reported in her cognitive or adaptive functioning after the first resection; following the second resection (i.e., five months later), significant changes were observed in her daily life from both a cognitive and adaptive perspective. Specifically, the patient and her partner noticed changes in her language functioning, including difficulties processing verbal information (e.g., understanding what others say, following instructions provided to her), word-finding difficulties, and fluency problems (e.g., sound or word substitutions). Changes in her ability to retain information were noted (e.g., appointment times, names of grandchildren). Her partner noted increased frustration in response to minor stressors. Changes in peripheral vision were reported; she refrained from driving due to this change. Variability in her adaptive functioning was also noted; she required assistance with many of the instrumental tasks that she had previously managed independently (e.g., managing household finances, keeping track of medications). No changes were noted in her ability to complete self-care tasks (e.g., dressing, grooming, bathing, toileting).
Neurology and Neuroimaging Findings
In August 2023, an initial brain CT scan revealed a left temporal lobe mass with extensive vasogenic edema and a significant midline shift of 4.5mm. In September 2023, a brain MRI confirmed a 3cm rim-enhancing mass in the left temporal lobe with surrounding edema, extending to the left basal ganglia and hemithalamus. The first resection was conducted at that time. A CT scan conducted two days post-surgery revealed residual tumor, surgical hemorrhage, continued midline shift, pneumocephalus, and a small volume of subarachnoid hemorrhage.
MRI spectroscopy from January 2024, compared to the brain MRI from the same month revealed FLAIR hyperintense signal in the left temporoparietal white matter adjacent to the surgical resection. A head CT/CTA and MRI studies from February 2024 revealed edema in the left temporoparietal lesion with a mass lesion measuring 2.8cm x 2.8cm.
Neuropsychological Findings
The patient was oriented to person, place, and time. She exhibited intact insight. Her premorbid intellectual functioning was presumed to be average, based on her educational and vocational history. On neuropsychological testing, she exhibited average visual-spatial construction, visual-motor integration, and visual perception. She exhibited appropriate spontaneous speech (e.g., singing) and preserved grammar and syntax. The most notable dysfunction was in expressive and receptive language domains. On formal measures of expressive language functioning, she demonstrated significant weaknesses in areas of fluency, repetition of speech, and confrontation naming. She was observed to have significant difficulty following complex, multi-step instructions, and conversational speech that was offered quickly. Although measures of learning, memory, attention, and executive functioning were selected carefully, taking her language deficits into consideration, it is likely that her language weaknesses impacted her performance across these other cognitive domains, as her performance fell substantially below age-expectations across these skills as well. Executive dysfunction in tasks with low language demands (e.g., visual scanning, sequencing, set-shifting) was present.
Treatment Recommendations
The alignment between her language impairments evident on cognitive testing, in conjunction with the imaging findings of a left temporal lesion, provided concrete data to guide subsequent interventions, including speech-language therapy and cognitive rehabilitation programs. Our patient exhibited preserved singing abilities, despite significant deficits in spoken language. While singing may not be an ideal long-term strategy for rehabilitation, it was recommended as an avenue to consider for preserving her expressive communication abilities.
Discussion
This case illustrates clear connections between tumor size, tumor location, and method of treatment with the cognitive outcomes identified through neuropsychological testing. However, this case also underscores the importance of baseline testing within the field of neuro-oncology. Unfortunately, this case is without baseline data (i.e., testing prior to the first resection); baseline evaluations not only assist in determining a patient’s functioning prior to the identification of the tumor, but establishes an understanding of functioning prior to treatment for later comparison in the face of waxing and waning and/or deterioration. Although we may rely on tumor and treatment characteristics and typical neuropsychological outcomes to predict areas of deficit, each patient presents with a unique premorbid cognitive profile, thus increasing the importance of baseline data.
Baseline neuropsychological testing establishes a cognitive profile before treatment begins and identifies subtle deficits that might not be immediately evident from neuroimaging alone. Baseline data also offers opportunities for individualized treatment planning and cognitive rehabilitation. Offering baseline measures to monitor recovery or decline over time will allow for timely adjustments in rehabilitation strategies. By quantifying deficits in areas like language, memory, attention, and executive functioning, the neuropsychological assessment informs surgical approaches and anticipates potential postoperative challenges.
Baseline data can also be used to reduce potential decline in QoL that may be associated with brain tumors. The long-term implications of treatments for brain tumors (i.e., surgery, chemotherapy, and radiation therapy) on QoL can be profound, with significant effects across cognitive, emotional, physical, and social domains. If we can identify premorbid areas of risk with regard to QoL (e.g., financial stressors, pre-existing mood disorders, poor social support), better support and interventions can be implemented to alleviate the degree of decline in QoL in an individualized way.
Neuropsychological data assist with the long-term monitoring of a patient’s cognitive functioning, but they also have the potential to inform treatment planning. With baseline data, we may have been able to be more precise in understanding cognitive change over time for our patient. We also may have been able to predict pre-existing risk factors to our patient’s long-term QoL. Baseline neuropsychological data should be considered imperative, as it allows for more individualized approaches to understanding the cognitive, emotional, and behavioral changes that a patient may experience. Despite not having comparison data in our case, post-surgical neuropsychological evaluation still provided useful information in the treatment planning process, further highlighting the importance of including neuropsychologists within a patient’s treatment team.
References
Chieffo, D. P. R., Lino, F., Ferrarese, D., Belella, D., Della Pepa, G. M., & Doglietto, F. (2023). Brain tumor at diagnosis: From cognition and behavior to quality of life. Diagnostics, 13(3), 541. https://doi.org/10.3390/diagnostics13030541
Dharia, A. A., Miller, C., & Pearson, C. M. (2024). The role of neuropsychology in neurosurgical care: A review of the literature. Neurologic clinics, 42(4), 889–902. https://doi.org/10.1016/j.ncl.2024.05.013
Hoffnung, D. S. (2016). The role of neuropsychology in the assessment and management of CNS tumors. Clinics In Oncology, 1(1065). http://www.clinicsinoncology.com/open-access/pthe-role-of-neuropsychology-in-the-assessment-and-management-of-cns-tumorsp-1235.pdf
Parsons, M. W., & Dietrich, J. (2021). Assessment and management of cognitive symptoms in patients with brain tumors. American Society of Clinical Oncology Educational Book, 41, e90–e99. https://doi.org/10.1200/EDBK_320813
Parsons, M. W., & Sabsevitz, D. S. (2023). Cognitive issues in patients with IDH mutant gliomas: from neuroscience to clinical neuropsychology. Journal of Neuro-Oncology, 162, 525–533. https://doi.org/10.1007/s11060-023-04289-4

Shannon Casey, PsyD
Correspondence: shannon.casey@npevaluation.com

Amanda Rivera Martinez, MS
Correspondence: amanda.rivera@npevaluation.com

Irene Piryatinsky, PhD, ABPP
Board Certified in Clinical Neuropsychology
Correspondence: info@npevalution.com